Correlation Between Royalty Pharma and Krystal Biotech

Can any of the company-specific risk be diversified away by investing in both Royalty Pharma and Krystal Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Royalty Pharma and Krystal Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Royalty Pharma Plc and Krystal Biotech, you can compare the effects of market volatilities on Royalty Pharma and Krystal Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Royalty Pharma with a short position of Krystal Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Royalty Pharma and Krystal Biotech.

Diversification Opportunities for Royalty Pharma and Krystal Biotech

0.59

Correlation Coefficient

Royalty Pharma  Krystal Biotech

Very weak diversification

The 3 months correlation between Royalty and Krystal is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Royalty Pharma Plc and Krystal Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Krystal Biotech and Royalty Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Royalty Pharma Plc are associated (or correlated) with Krystal Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Krystal Biotech has no effect on the direction of Royalty Pharma i.e., Royalty Pharma and Krystal Biotech go up and down completely randomly.

Pair Corralation between Royalty Pharma and Krystal Biotech

Given the investment horizon of 90 days Royalty Pharma Plc is expected to generate 0.76 times more return on investment than Krystal Biotech. However, Royalty Pharma Plc is 1.32 times less risky than Krystal Biotech. It trades about 0.19 of its potential returns per unit of risk. Krystal Biotech is currently generating about 0.1 per unit of risk. If you would invest  2,515  in Royalty Pharma Plc on December 29, 2024 and sell it today you would earn a total of  622.00  from holding Royalty Pharma Plc or generate 24.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Royalty Pharma Plc  vs.  Krystal Biotech

Royalty Pharma Plc

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Royalty Pharma Plc are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Royalty Pharma showed solid returns over the last few months and may actually be approaching a breakup point.

Krystal Biotech

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Krystal Biotech are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Krystal Biotech unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Royalty Pharma and Krystal Biotech

The main advantage of trading using opposite Royalty Pharma and Krystal Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Royalty Pharma position performs unexpectedly, Krystal Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will offset losses from the drop in Krystal Biotech's long position.

The idea behind Royalty Pharma Plc and Krystal Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.